Full-Year Revenue Growth
Revenue for fiscal 2025 was $52.7 million, representing +8% year-over-year growth versus 2024, with broad-based growth across Cyclo G6, medical retina and surgical retina, and both U.S. and international businesses.
Strong Q4 Performance
Fourth-quarter revenue was $14.7 million, a +16% year-over-year increase (Q4 was a 14-week quarter), marking the strongest quarterly growth rate of the year and driven by higher retina and glaucoma probe sales.
Profitability and Cash Flow Milestones
IRIDEX delivered positive adjusted EBITDA for the full year (adjusted EBITDA $817,000 vs $611,000 prior year) and generated positive cash flow from operations in Q4. Net loss narrowed to $0.2 million (loss per share $0.01) vs $0.8 million in prior year.
Material Operating Expense Reductions and Cost Savings Plans
Operating expenses were reduced 22% year-over-year (full year); Q4 operating expenses totaled $5.5 million (a 10% reduction vs prior-year quarter). Actions include relocation of certain G&A functions (estimated ~$165k in quarterly savings beginning Q1 2026) and a planned HQ relocation expected to reduce fixed costs by ~$600k annually.
Product and Commercial Momentum
Glaucoma probe sales: Q4 probes sold 15,900 vs 13,300 prior-year (+~19%); full-year probes 57,800 vs 55,400 (+~4%). Full-year G6 systems sold 133 vs 125 (up ~6%). Retina revenue increased 22% in Q4 to $8.9 million driven by PASCAL and medical/surgical retina systems. Sales team converted ~$1.0M of business from the AAO meeting.
Improved Cash Position and Cash Usage
Cash and cash equivalents improved to approximately $6.0 million (up ~$400k from ~$5.6M) and cash use for 2025 was $2.1 million, an improvement of 71% versus 2024; management expects further cash generation and positive full-year cash flow in 2026.